ESMO 2026 | Comparing the toxicity of HS-20122, a bispecific ADC, to other ADCs
Hongyun Zhao, MD, Sun Yat-sen University Cancer Center, Guangzhou, China, comments on the toxicity profile of a HS-20122, a novel EGFR/cMET bispecific antibody-drug conjugate (ADC), noting that while hematological toxicity is a common grade 3 and above toxicity, it is manageable and comparable to single-target EGFR ADC or cMET ADC. The bispecific ADC has a similar data sheet to single-target ADCs, with manageable on-target toxicity, including HFR-targeted toxicity such as diarrhea and stomatitis. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
